News Release

Auxly on a Hot Streak Heading into a Summer Packed with New Products

TORONTO, July 12, 2021 — Auxly Cannabis Group Inc. (TSX – XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the cannabis products market, is excited to present its product line-up for a summer season filled with brand-new offerings and inspired flavours across multiple categories, including dried flower, vapes, edibles, oil, capsules and concentrates.

Today’s announcement comes as the Company is experiencing success with its previously announced strategic expansion into the dried flower market, including the introduction of dried flower offerings under its Back Forty brand. Auxly’s Back Forty Pine Kush launched in March and it has quickly become one of the most popular flower brands in Canadai. The success of the Back Forty flower launch has helped Auxly capture approximately 2% of the entire national cannabis flower market (dried flower and pre-rollsii) for the month of June. The Company is delighted with its early success in a segment (dried flower) that accounts for nearly 75% of all Canadian cannabis sales to-date this quarter, or more than $2 billion in sales annuallyiii.

With its leadership position in cannabis 2.0 products and the added success of dried flower sales, Auxly has achieved a 5.2% share of the national market for the month of June, as confirmed by Headset Canadian Insights. Further, the Company has moved up to the #6 position among Canadian Licensed Producers for the month of Juneiv.

Now, Auxly looks ahead to a summer 2021 lineup designed to delight Canadian cannabis consumers and capture even more of the dried flower market, including exciting new cultivars under the Back Forty brand and the launch of Back Forty pre-rolls.

“Through a focused strategy built on deep consumer insights and executional excellence, we are proud to continue to grow our market share and make a successful entry into the dried flower segment,” said Hugo Alves, CEO of Auxly. “We are excited to continue introducing new products that are responsive to our consumers’ needs, including a more robust line-up of dried flower and pre-roll offerings under our Back Forty and Kolab brands.”

“Canadians deserve something special after a year and a half of pandemic life, and we wanted to make sure our brands rose to the occasion,” said Andrew MacMillan, Senior Vice President, Commercial, Auxly. “Our team of product developers and marketing experts have leveraged consumer insights this summer to bring a suite of high-quality and unique cannabis products that we believe will continue to drive sales and gain meaningful market share for Auxly.”

Here’s a look at the new products Canadian cannabis consumers can look forward to this summer from Auxly’s in-house brands Kolab ProjectBack FortyForay and Dosecann. More information about these product launches will be announced over the coming weeks. The following products will be available across Canada:

Flower & Pre-rolls:

  • Back Forty Animal Mints and Wedding Pie flower. Organically grown, Animal Mints and Wedding Pie are exceptional strains with high THC potencies. These new cultivars will land in the Back Forty where consumers find a better experience for less.
  • Back Forty 40s pre-rolls. 40s are machine-rolled straight joints manufactured with state-of-the-art pre-roll technology for a consistent, quality pre-roll that burns evenly with enhanced airflow and flavour. Back Forty 40s will launch with Back Forty’s new organically grown strains Animal Mints and Wedding Pie.
  • Kolab Project x Robinsons Growers Series Purple Kush. This summer crossover sees Robinsons’ heavy hitting Purple Kush joining the popular Kolab Project Growers Series, providing cannabis enthusiasts with Robinsons’ superior quality cannabis uplifted by the Kolab Project Growers Series platform.

Edibles:

  • Kolab Project 132 Series Live Resin Black Cherry Punch soft chew. A broad-spectrum experience, Canada’s first live-resin soft chew includes aromatic Black Cherry Punch live resin with cherry and floral undertones.
  • Back Forty S’mores chocolate. Back Forty’s first edible captures the iconic Canadian campfire treat by combining the flavours of marshmallow, graham crackers and, of course, chocolate.

Kolab Project 232 Series maximizes the flavour and natural expression of the plant for a true-to-strain experience across multiple categories. This summer, Kolab Project puts Slurricane in the spotlight in the following categories:

  • Vapes1g Live Terpene 510 vape cartridge. Slurricane joins Ice Cream Cake and Black Cherry Punch – both newly launched in the Ontario market.
  • Concentrates: Fans of Kolab Project’s best-selling THCA Diamonds will be excited to learn that the brand is issuing a new installment with the Slurricane strain.     

Oils & Capsules:

  • Dosecann expands its offerings featuring Auxly’s exclusive, proprietary Ahiflower® Seed Oil and CBD this summer. CBD Omega Lemon Lavender oil and CBD 50 Omega capsules combine high-potency, broad-spectrum cannabinoids with Ahiflower for a sustainably sourced, plant-based, non-GMO source of essential Omega 3 and 6.         

In addition to the above national product launches, Auxly is making the following unique edible products available to select provinces. More information about the distribution of these products will be announced in coming weeks:

  • Back Forty Sour Grape and Sour Cherry soft chews. These vegan soft chews join S’mores as the inaugural edibles for Back Forty, in flavours that recall simpler times.
  • Foray Strawberry Milkshake White Chocolate. Nothing says summer like a strawberry milkshake. Perhaps Foray’s tastiest edible yet, Strawberry Milkshake White Chocolate is a fresh take on an old-fashioned favourite, perfectly blended to create and rich and creamy mouthfeel, bursting with delicious berry flavour and notes of white chocolate.

ON BEHALF OF THE BOARD

Hugo Alves” CEO

In the country’s largest market, Ontario, Back Forty Pine Kush in 28g units was the #5 dried-flower SKU in the quarter ending June 30, 2021 (source: OCS sales data, as of July 1, 2021); in British Columbia, Back Forty dried flower was the sixth best-seller for Q2, 2021, capturing approximately 3% of the retail market (source: Headset Canadian Insights, British Columbia dried-flower sales, by brand, as of July 1, 2021).
Headset Canadian Insights, Total Canadian Cannabis dried-flower and pre-roll sales, as of July 1, 2021
Source: https://www.bnnbloomberg.ca/cannabis-canada-weekly-canadians-bought-2b-of-dried-flower-last-year-1.1591442

Headset Canadian Insights, Total Canadian Cannabis sales, as of July 1, 2021

About Auxly Cannabis Group Inc. (TSX: XLY) (OTCQX: CBWTF)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

For more information please contact:
Scott Campbell, 647-402-4957, press@auxly.com

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes but is not limited to: the successful production and launch of current and future Company products; the Company’s execution of its product development, commercialization strategy, and expansion plans; the ability of the Company to maintain and grow its market share; the relevance of the Company’s proposed products; consumer preferences; political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to whether: there is acceptance and demand for current and future Company products by consumers and provincial purchasers; and general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party sources, the accuracy of which has not been verified by Auxly. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Strengthens Financial Position with the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative Cannabis

TORONTO, Ontario, July 6, 2021 – Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“) a leading consumer packaged goods company in the cannabis products market, is pleased to announce the implementation of amendments to certain provisions of its previously issued $123 million debenture (the “Debenture”) and investor rights agreement (the “Investor Rights Agreement”) dated September 25, 2019 (collectively, the “Amendments”) with its strategic partner, Imperial Brands PLC (“Imperial Brands”), pursuant to the terms of the previously announced amending agreement dated April 19, 2021.

Pursuant to the Amendments, Imperial and Auxly have: (i) extended the maturity date of the Debenture by 24 months from September 25, 2022 to September 25, 2024; (ii) provided Imperial with the right, on an annual basis, to convert any or all of the accrued and unpaid interest on the Debenture then outstanding into Common Shares (the “Interest Conversion Election”), at a conversion price equal to the five-day volume weighted average trading price of the Common Shares on the date that Interest Conversion Election is made; (iii) provided that the payment of interest under the Debenture, which currently accrues at a rate of 4% per annum and is payable annually, will remain unchanged but will be payable on maturity of the Debenture; and (iv) re-instated certain approval rights of Imperial under the Investor Rights Agreement.

The Amendments were subject to, among other things, the Company obtaining minority shareholder approval in accordance with Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions, which was obtained at the Company’s annual and special meeting of shareholders held on June 28, 2021.

The Company is also pleased to announce that it has completed the sale of its interest in 2368523 Ontario Limited (d/b/a Curative Cannabis) to a private purchaser for total proceeds to the Company of $6 million.   The Company acquired substantially all the shares and assets of Curative Cannabis pursuant to a foreclosure order issued on November 27, 2019, which assets included a cannabis cultivation facility located in Chatham-Kent, Ontario. The facility has remained non-operational since the foreclosure and while exploring all possible options with respect to the use, commercialization and/or sale of the asset the Company determined such asset was not essential to the Company’s operations and strategy. The disposition of this non-core asset allows the Company to strengthen its financial position with non-dilutive capital that it can deploy into its core business.

ON BEHALF OF THE BOARD

“Hugo Alves” CEO

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team: 

Email: IR@auxly.com

Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:

Email: press@auxly.com 

Auxly’s head office is located at 777 Richmond St. W, Unit 002, Toronto, ON M6J 0C2. Imperial Brand’s head office is located at 121 Winterstoke Road, Bristol, UK BS3 2LL.

Early Warning Disclosure

An affiliate of Imperial Brands holds the Debenture and assuming the Debenture is exercised in full as of the date hereof (but excluding any exercise of the Interest Conversion Election by the holder of the Debenture), Imperial Brands and its affiliates would have beneficial ownership of 157,983,592 Common Shares or approximately 16% of the issued and outstanding Common Shares (calculated on a non-diluted basis).

Imperial Brands intends to review its investment in the Company on a continuing basis and may, subject to the terms of the Investor Rights Agreement, purchase or sell common shares, either on the open market or in private transactions, or exercise the Debenture in the future, in each case, depending on a number of factors, including general market and economic conditions and other factors and conditions Imperial Brands deems appropriate.

An amended early warning report will be filed by Imperial Brands with applicable Canadian securities regulatory authorities. To obtain a copy of the early warning report, please contact Daniel Glavin at 416- 869-5500.

Notice Regarding Forward Looking Information:  

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the Company’s execution of its product development, commercialization strategy and expansion plans; consumer preferences; political change; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information included in this release including, but not limited to, whether: general economic, financial market, legislative, regulatory, competitive and political conditions in which Auxly operates will remain the same. Additional risk factors are disclosed in the annual information form of Auxly for the financial year ended December 31, 2020 dated April 23, 2021.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this news release is based on information currently available and what management believes are reasonable assumptions. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this news release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Announces Results of Annual General and Special Meeting of Shareholders

TORONTO, June 29, 2021 — Auxly Cannabis Group Inc. (TSX- XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“) announced today the voting results from its annual general and special meeting of shareholders held on June 28, 2021 (the “Meeting”).

A total of 132,758,409 common shares of the Company, representing 17.62% of the issued and outstanding common shares of the Company, were voted in connection with the Meeting by shareholders and proxy holders.

All of the matters put forward before the Company’s shareholders for consideration and approval, as set out in the Company’s information circular dated May 20, 2021 (the “Circular”), were approved by the requisite majority of the votes cast at the Meeting. The results are set out below.

Each of the directors listed as a nominee in the Circular was elected as a director of the Company at the Meeting. The detailed results can viewed here at GlobeNewswire.

Auxly Announces Closing of $17 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

TORONTO, ON – June 14, 2021 – Auxly Cannabis Group Inc. (“Auxly” or the “Company”) (TSX: XLY) (OTCQX: CBWTF) is pleased to announce the closing of its bought deal short form prospectus offering pursuant to which the Company issued 54,763,000 units of the Company (the “Units“) at a price of $0.315 per Unit for gross proceeds to the Company of $17,250,345 (the “Offering“), including the full exercise of the over-allotment option.

The Offering was led by ATB Capital Markets Inc. as sole bookrunner and Cantor Fitzgerald Canada Corporation acting as co-lead underwriters, together with a syndicate of underwriters including Desjardins Capital Markets, Raymond James Ltd., and Mackie Research Capital Corporation (collectively, the “Underwriters”).  A.G.P./Alliance Global Partners was acting as the sole U.S. sub-agent and financial advisor to the Company in connection with the Offering in the United States.

Each Unit is comprised of one common share of the Company (each a “Common Share“) and one-half of oneCommon Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.38 at any time up to 36 months from closing of the Offering.

The net proceeds from the Offering will be used to continue to pursue strategic growth initiatives, including continued development, commercialization and expansion of its product portfolio, and for general corporate purposes.

The Units were offered by way of a prospectus supplement (the “Prospectus Supplement“) to the Company’s short form base shelf prospectus dated March 18, 2021 (the “Base Shelf Prospectus“), which has been filed in those provinces of Canada as the Company and the Underwriters may designate (excluding Quebec) pursuant to National Instrument 44-101 – Short Form Prospectus Distributions and National Instrument 44-102 – Shelf Distributions. The Units were also offered in the United States on a private placement basis pursuant to an appropriate exemption from the registration requirements under applicable U.S. law.

The Prospectus Supplement and the Base Shelf Prospectus contain important detailed ‎information about the Offering. Copies of the Prospectus Supplement and the Base Shelf ‎Prospectus are available on the Company’s profile on SEDAR at www.sedar.com. ‎Copies of the Prospectus Supplement and the Base Shelf Prospectus may also be obtained in ‎Canada from ATB Capital Markets Inc. at Suite 410, 585 8 Avenue SW Calgary, AB T2P 1G1 or by email at prospectus@atb.com.

No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

ON BEHALF OF THE BOARD 

Hugo Alves CEO 

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team:

Email: IR@auxly.com

Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:

Email: press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. In particular, this news release contains forward-looking statements pertaining to expected use of proceeds for the Offering.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information included in this release including, but not limited to: general economic, financial market, legislative, regulatory, competitive and political conditions in which Auxly operates will remain the same. Additional risk factors are disclosed in the annual information form of Auxly for the financial year ended December 31, 2020 dated April 23, 2021.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this news release is based on information currently available and what management believes are reasonable assumptions. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this news release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Announces $15.0 Million Bought-Deal Public Offering

TORONTO, ON – June 9, 2021 – Auxly Cannabis Group Inc. (“Auxly” or the “Company”) (TSX: XLY) (OTCQX: CBWTF) is pleased to announce that it has entered into an agreement pursuant to which ATB Capital Markets Inc. (“ATB”), as sole bookrunner, and Cantor Fitzgerald Canada Corporation, acting as co-lead underwriters of the Offering, together with a syndicate of underwriters (collectively, the “Underwriters”), will purchase 47,620,000 Units of the Company (the “Units”), on a bought-deal basis at a price per Unit of $0.315 (the “Issue Price”) for gross proceeds of $15,000,300 (the “Offering“). A.G.P./Alliance Global Partners is acting as the sole U.S. sub-agent and financial advisor to the Company in connection with the Offering in the United States.

Each Unit shall be comprised of one common share of the Company (each a “Common Share“) and one-half of oneCommon Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.38 at any time up to 36 months from closing of the Offering.

The Company has granted the Underwriters an option (the “Underwriters’ Option”) to increase the size of the Offering by up to an aggregate number of Units equal to 15% of the total number of Units issued under the Offering, such Underwriters’ Option being exercisable at any time and from time to time up to 30 days following the closing of the Offering.

The Company intends to use the net proceeds to continue to pursue strategic growth initiatives, including continued development, commercialization and expansion of its product portfolio, and for general corporate purposes.

The closing of the Offering is expected to occur on or about the week of June 14, 2021 (the “Closing”), or such later or earlier date as the Underwriters and the Company may agree upon,and is subject to the Company receiving all necessary regulatory approvals, including the approval of the necessary securities regulatory authorities.

The Units will be offered by way of a prospectus supplement (the “Prospectus Supplement“) to the Company’s short form base shelf prospectus dated March 18, 2021 (the “Base Shelf Prospectus“), which will be filed in those provinces of Canada as the Company and the Underwriters may designate (excluding Quebec) pursuant to National Instrument 44-101 – Short Form Prospectus Distributions and National Instrument 44-102 – Shelf Distributions. The Units may also be offered in the United States on a private placement basis pursuant to an appropriate exemption from the registration requirements under applicable U.S. law.

The Prospectus Supplement and the Base Shelf Prospectus will contain important detailed ‎information about the Offering. Copies of the Prospectus Supplement, following the filing thereof, and the Base Shelf ‎Prospectus will be available on the Company’s profile on SEDAR at www.sedar.com. ‎Copies of the Prospectus Supplement and the Base Shelf Prospectus may also be obtained in ‎Canada from ATB Capital Markets Inc. at Suite 410, 585 8 Avenue SW Calgary, AB T2P 1G1 or by email at prospectus@atb.com.

No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

ON BEHALF OF THE BOARD 

Hugo Alves CEO 

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team:

Email: IR@auxly.com

Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:

Email: press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the receipt of the necessary regulatory approvals for the Offering; the timing and proposed completion of the Offering; the expected use of proceeds of the Offering by the Company;  the pricing of the Offering;, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information included in this release including, but not limited to: whether the Company can complete the Offering on the anticipated terms and timeline; whether the Company can obtain regulatory approval of the Offering on the proposed terms and timeline; and general economic, financial market, legislative, regulatory, competitive and political conditions in which the Company operates will remain the same. Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2020 dated April 23, 2021.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this news release is based on information currently available and what management believes are reasonable assumptions. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this news release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Announces Annual General and Special Meeting of Shareholders and COVID-19 Precautionary Guidance

TORONTO, Ontario, May 31, 2021 – Auxly Cannabis Group Inc. (TSX- XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“) announced today that it will hold its Annual General and Special Meeting of Shareholders (the “Meeting”) on Monday, June 28, 2021 at 2:00 p.m. EST at the offices of Bennett Jones LLP, 3400 One First Canadian Place, Toronto, Ontario, M5X 1A4. 

COVID-19 Guidance

The Company is strongly discouraging physical attendance at the meeting to proactively deal with potential issues arising from the unprecedented public health impact of COVID-19 and to limit and mitigate risks to the health and safety of its communities, shareholders, employees, directors and other stakeholders. The Meeting will not be open to the general public and will be restricted to registered shareholders (who are also strongly discouraged from attending) and duly appointed proxyholders only. To ensure compliance with public health guidance on public gatherings, registered shareholders who wish to attend the Meeting are required to provide the Company with at least 48 hours advance notice, and any shareholder who does not provide such notice and receive approval from the Company to attend will not be admitted to the Meeting. Notice can be provided at IR@auxly.com.

To allow shareholders to follow the conduct of the Meeting, the Company is providing an audio teleconference that can be used by participants to listen to the Meeting in real time.

Teleconference Details

Date: Monday June 28, 2021

Time: 2:00 p.m. EST

North American Toll Free: 1-888-664-6383

Conference ID: 94023704

Please note that shareholders will not be entitled to vote at, or otherwise participate in, the Meeting by way of teleconference or other electronic means, and so this year, more than ever, we strongly encourage shareholders to vote in advance of the Meeting in accordance with the instructions provided in the materials for the Meeting, including the Management Information Circular, which has been mailed to shareholders and is available on SEDAR as well as the Company’s website.  

There will be no formal question and answer period following the Meeting and presentation by management, however, shareholders are welcome to submit questions in advance to the Investor Relations inbox at IR@auxly.com, and the Company will respond to select questions submitted before June 21, 2021 on the call.

ON BEHALF OF THE BOARD

“Hugo Alves” CEO

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team: 

Email: IR@auxly.com

Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:

Email: press@auxly.com 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Reports Q1 2021 Financial Results

TORONTO, May 28, 2021 — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“) today released its financial results for the three months ended March 31, 2021. These filings and additional information regarding Auxly are available for review on SEDAR at www.sedar.com.

Q1 2021 Highlights and Subsequent Events

  • — Recorded net revenues of $10M for the three months ended March 31, 2021, an increase of 1% from the same period in 2020.
  • — Maintained leadership position in Cannabis 2.0 product sales with approximately 12.6% national market share1 in the quarter.
  • — SG&A declined another 5% from the previous quarter.
  • — Continued to launch new innovative products to the Canadian market with the introduction of the Company’s first cannabis concentrate, 232 Series Diamonds under its Kolab Project brand and an industry-leading, high-potency topical, Dosecann Daily Relief CBD cream.
  • — Welcomed Andrea Fraser to the Auxly Family as Chief People Officer.
  • — Further strengthened the Company’s balance sheet with a $8M private placement offering of units.

Read full release on GlobeNewswire here.

Auxly Financials and Filings.

Auxly Reaches an Agreement With Myconic Capital to Sell KGK Science For Up to $16.5 Million in Value

TORONTO, May 27, 2021 — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, announced today that it has entered into a definitive agreement with Myconic Capital Corp. (NEO: MEDI) (“Myconic”), an investment issuer with a diversified portfolio focused on emerging companies, pursuant to which Myconic will acquire all of the issued and outstanding shares of KGK Science Inc. (“KGK”) (the “Transaction”) for up to $16.5 million in value comprised of:

  • $12.5 million purchase price from Myconic in the form of:
    • $1.5 million in cash payable on the closing date of the Transaction;
    • $1.0 million in cash payable six months after the closing date of the Transaction; and
    • $10.0 million in common shares in the capital of Myconic (“Myconic Shares”) at a price per Myconic Share of $1.55 (being 6,451,612 Myconic Shares) all to be issued on the closing date of the Transaction, with equal tranches becoming freely tradeable on the four, six, nine and 12 month anniversaries of the closing date of the Transaction;
  • $1.5 million milestone payment, payable in cash or Myconic Shares, at the option of Myconic, if KGK achieves gross revenues of $8 million in any 12-month period during the two years following the closing date of the Transaction; and
  • $2.5 million credit against future KGK services, reflected in a 10-year service agreement between Auxly and KGK.

The Transaction is expected to close on or around the week of June 7, 2021 and is subject to customary closing conditions and regulatory approvals, including the approval of the NEO Exchange.

“This agreement with Myconic is a win-win for Auxly and its shareholders in both the short and long-term, as the additional capital can be deployed into our core business and accelerates Auxly’s path to profitability, while continuing our long-standing relationship with KGK to leverage their deep clinical expertise as we continue to bring innovative cannabis products to market that meet our consumer promise of quality, safety and efficacy,” said Hugo Alves, CEO, Auxly. “KGK is an outstanding CRO that knows how to unlock value in emerging industries through clinical work and will be an excellent fit with the team at Myconic.”

“This is an exciting day for KGK as we look to bring our years of experience as a leading CRO into the field of psychedelics research, which holds great promise for helping people overcome a wide range of illnesses,” said Najla Guthrie, President & CEO, KGK. “We’ve gained invaluable insight from our partnership with Auxly and look forward to continuing our relationship and helping them bring safe and effective cannabis products to market.”

“The investment that Myconic is making to acquire KGK is very exciting and I look forward to welcoming the KGK team and their valuable expertise to our company,” said Robert Meister, Chief Executive Officer of Myconic. “On behalf of the Board of Directors, I would like to commend Auxly on their professionalism and transparency throughout the Transaction thus far and look forward to our companies working together for many years into the future, long after the closing date,” added Mr. Meister.

With the sale of KGK, Auxly gains additional liquidity to support the Company’s ongoing commercial operations as it continues to expand its product offering in Canada and execute on its business strategy.

ON BEHALF OF THE BOARD
“Hugo Alves” CEO

About Myconic Capital Corp. (CSE: MEDI)

Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health and wellness sectors.

About Auxly Cannabis Group Inc. (TSX: XLY)

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team: 
Email: IR@auxly.com
Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:
Email: press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the receipt of the necessary regulatory approval for the Transaction and the timing of such approval; the timing and proposed completion of the Transaction; the Company’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: the Transaction can be completed on the anticipated terms and timeline; and general economic, financial market, regulatory and political conditions in which the Company operates will remain the same. Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2020 dated April 23, 2021.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by Auxly. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release. 

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Announces Closing of Private Placement of Units for Gross Proceeds of $8.0 Million

TORONTO, May 20, 2021 — Auxly Cannabis Group Inc. (“Auxly” or the “Company”) (TSX: XLY) (OTCQX: CBWTF) is pleased to announce that it has closed its previously announced private placement offering of units (the “Units“) to an institutional investor (the “Investor”) for gross proceeds of approximately $8.0 million (the “Offering”). Pursuant to the Offering, the Company issued 23,880,598 Units of the Company at a price of $0.335 per Unit. ATB Capital Markets Inc. acted as exclusive agent on the Offering.

Each Unit is comprised of one common share of the Company (each a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant entitles the Investor to purchase one Common Share at an exercise price of $0.42 at any time up to 36 months from closing of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

ON BEHALF OF THE BOARD 

Hugo Alves CEO 

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a vertically integrated cannabis company dedicated to bringing branded cannabis products to market that consumers love and trust. Our team of professionals and cannabis enthusiasts are united by a shared commitment to quality and our consumers. We build powerful value propositions with brands that connect and products that deliver on our consumer promise of quality, safety and efficacy.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@auxly.com 
Phone: 1.833.695.2414

Media Enquiries (only): 
For media enquiries or to set up an interview please contact:
Email: press@auxly.com  

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the expected use of proceeds of the Offering; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Announces $8.0 Million Private Placement

TORONTO, May 13, 2021 — Auxly Cannabis Group Inc. (“Auxly” or the “Company”) (TSX: XLY) (OTCQX: CBWTF) is pleased to announce that it has entered into an agreement with an institutional investor (the “Investor”) pursuant to which the Investor has agreed to purchase, on a private placement basis, 23,880,597 units (the “Units“) of the Company at a price of $0.335 per Unit for aggregate gross proceeds of approximately $8.0 million (the “Offering“). ATB Capital Markets Inc. is acting as exclusive agent on the Offering.

Each Unit shall be comprised of one common share of the Company (each a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the Investor to purchase one Common Share at an exercise price of $0.42 at any time up to 36 months from Closing (as defined below).

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The closing of the Offering is expected to occur during the week of May 17, 2021 (the “Closing”), or such later or earlier date as the Investor and the Company may agree upon, and is subject to the completion of formal documentation and the Company receiving all necessary regulatory approvals, including the approval of the Toronto Stock Exchange. The Units will be offered pursuant to applicable exemptions from the prospectus requirements of Canadian securities laws and shall be subject to a customary four-month hold period under Canadian securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.   This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

ON BEHALF OF THE BOARD 

Hugo Alves CEO 

About Auxly Cannabis Group Inc. (TSX: XLY)
Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry-first movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@auxly.com
Phone: 1.833.695.2414

Media Enquiries (only): 
For media enquiries or to set up an interview please contact:
Email: press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the proposed completion of, and the expected use of proceeds of, the Offering; the Company’s response to the COVID-19 pandemic; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.
Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2020 dated April 23, 2021.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward‐looking information.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Appoints First Chief People Officer

 TORONTO, Ontario, May 5, 2021 – Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, is pleased to announce that it has hired Andrea Fraser as Chief People Officer. In this new role, Ms. Fraser will lead all aspects of the Company’s human resources, including crafting talent acquisition strategies, promoting inclusion in the workplace and further developing and evaluating career paths to meet the Company’s business goals. Ms. Fraser will also manage Auxly’s ongoing response to the impacts of COVID-19 as it relates to its employees and office spaces. 

Ms. Fraser brings extensive experience and deep knowledge of leading People and Culture strategy and initiatives for multinational CPG and digital marketing companies, most recently working as Director, Global Human Resources at Tilray. 

“We are delighted to welcome Andrea to the Auxly Family,” said Hugo Alves, CEO of Auxly. “We believe she is the right leader to help us continue building an engaged, inclusive and high-performing culture at Auxly.” 

Ms. Fraser commented, “I couldn’t be more excited to be joining Auxly as its new Chief People Officer. The highly engaged culture that Auxly has created is truly special and I look forward to helping them take these strengths to a new level of performance and success.” 

ON BEHALF OF THE BOARD 

“Hugo Alves” CEO 

About Auxly Cannabis Group Inc. (TSX: XLY) 

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market. 

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations: 

For investor enquiries please contact our Investor Relations Team: 

Email: IR@auxly.com 

Phone: 1.833.695.2414 

Media Enquiries (only): 

For media enquiries or to set up an interview please contact: 

Email: press@auxly.com 

Notice Regarding Forward Looking Information: 

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the Company’s response to the COVID-19 pandemic; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally. 

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Ms. Fraser brings extensive experience and deep knowledge of leading People and Culture strategy and initiatives for multinational CPG and digital marketing companies, most recently working as Director, Global Human Resources at Tilray. 

“We are delighted to welcome Andrea to the Auxly Family,” said Hugo Alves, CEO of Auxly. “We believe she is the right leader to help us continue building an engaged, inclusive and high-performing culture at Auxly.” 

Ms. Fraser commented, “I couldn’t be more excited to be joining Auxly as its new Chief People Officer. The highly engaged culture that Auxly has created is truly special and I look forward to helping them take these strengths to a new level of performance and success.” 

ON BEHALF OF THE BOARD 

“Hugo Alves” CEO 

About Auxly Cannabis Group Inc. (TSX: XLY) 

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market. 

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/. 2 

Investor Relations: 

For investor enquiries please contact our Investor Relations Team: 

Email: IR@auxly.com 

Phone: 1.833.695.2414 

Media Enquiries (only): 

For media enquiries or to set up an interview please contact: 

Email: press@auxly.com 

Notice Regarding Forward Looking Information: 

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the Company’s response to the COVID-19 pandemic; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally. 

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. 

View on GlobeNewswire here.

Dosecann Launches Industry-Leading, High-Potency Topical: Dosecann Daily Relief CBD Cream

TORONTO, Ontario, May 3, 2021 – Today Dosecann, an in-house brand owned by Auxly Cannabis Group Inc. (TSX – XLY) (“Auxly”), announces the launch of Dosecann Daily Relief CBD Cream, a new, high-strength, differentiated cannabis topical cream for Canadian wellness consumers. With 1,200mg of cannabidiol (CBD) per 60 ml unit, Dosecann Daily Relief CBD Cream has double the potency of any CBD topical currently available in the Canadian marketplace and is competitively priced to deliver the best value for a CBD topical[i]. Dosecann Daily Relief CBD Cream is available to order now for wholesalers across Canada, is available to consumers now in British Columbia and Saskatchewan and will also be available in Alberta in coming weeks.  

Dosecann Daily CBD Cream was developed by a team of scientists, researchers and formulation experts at Auxly’s state-of-the-art laboratory in Charlottetown, PEI, under the direction of Dr. Bob Chapman, Chief Science Officer, Dosecann.

“Topicals were among the very first products we conceived of at Dosecann and I’m extremely proud that after thorough development and testing, we’ve landed on a formula that we believe is the best in the marketplace,” said Dr. Chapman. “Consumers use topicals to provide daily relief from a wide variety of symptoms such as localized pain relief, muscle soreness, tension and inflammation. Our team was driven to ensure that Dosecann Daily Relief CBD Cream offers industry-leading potency along with a formulation designed to boost CBD penetration and provide the skin moisturizing properties of high-end skin creams.”

“We’re excited to launch Dosecann Daily Relief CBD Cream and expand our expertise in the 2.0 segment into topicals,” said Brad Canario, Brand Director, Auxly. “We know from research that topicals are a high-frequency segment, with nearly 50% of topical consumers using daily, and further, that amongst Canadian cannabis users, creams are the #1 topicals format. We believe we have a truly differentiated product for wellness consumers looking for daily relief from a variety of symptoms and, as always, we focused on our pillars of quality, safety and efficacy at every stage of product development.”

The proprietary Dosecann Daily Relief CBD Cream formula combines high-quality CBD extract with Natralipid™ Meadowfoam seed oil, a plant-based emollient found in high-end skin creams and valued for moisturization, transdermal barrier repair, skin penetration and unsurpassed stability. The result is a product that promotes the fast, effective absorption of high-quality CBD extract so that the cannabinoids can get where they’re needed quickly, all the while soothing the skin by locking-in moisture without leaving a greasy feeling behind. Dosecann Daily Relief CBD Cream has a mild, neutral bamboo scent and is packaged in a recyclable glass jar with a built-in seal to preserve freshness. 

Dosecann Daily Relief CBD Cream is the latest cannabis 2.0 release from Auxly, who achieved the #1 market-share position for Cannabis 2.0 products in 2020. With today’s launch, Dosecann expands its offering of natural, science-backed products, which includes oils and precision-dosed capsules made with omega-rich Ahiflower™ oil.

About Dosecann          
Dosecann is a world-class developer of innovative cannabis products for the wellness-focused consumer, wholly owned by Auxly Cannabis Group Inc.  Proudly processed at Auxly’s 52,000 sq. ft., state-of-the-art facility in Charlottetown, Prince Edward Island, Dosecann products are developed and manufactured on-site by a world-class team of scientists and experts, ensuring high-quality, precision and consistency. Dosecann’s wellness products, available at licensed cannabis retailers across Canada, consist of non-GMO capsules and oils. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science.

Learn more at dosecann.com and stay up to date at Twitter: @Dosecann; Instagram: @dosecann; Facebook: @dosecann.

About Auxly Cannabis Group Inc. (TSX: XLY) (OTCQX: CBWTF)  
Auxly is leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

For more information please contact:
Scott Campbell, 647-402-4957, press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes but is not limited to: Dosecann’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis, cannabis products and cannabis health products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to whether: there is acceptance and demand for current and future Dosecann products by consumers and provincial purchasers, and general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party sources, the accuracy of which has not been verified by Auxly. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock  Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021

TORONTO, Ontario, April 26, 2021 – Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a consumer packaged goods company in the cannabis products market, today released its fourth quarter and full year 2020 financial results. These filings and additional information regarding Auxly are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars except common shares (“Shares”) and per Share amounts.

2020 Highlights

  • – Recorded net revenues of $50.8 million in 2020, including $46.6 million in cannabis net revenues, an increase of 508% compared to 2019. 
  • – Fourth quarter net Cannabis revenues of $18.3 million.
  • – Achieved the #1 LP position in Canada for Cannabis 2.0 product sales[1] in 2020 with approximately 14% market share in the category. 
  • – Expanded into the Cannabis 1.0 market with the launch of Robinsons premium dried flower and
  • – Kolab Project Growers Series collaborations with Lotus Cannabis and Safari Flower Co.  
  • – Continued efforts to reduce SG&A which were below $10 million in the fourth quarter. 
  • – Further strengthened the Company’s balance sheet with financing transactions.

View full news release here.

Read on GlobeNewswire here.

Imperial Brands PLC Extends $123 Million Convertible Debenture and Defers Interest

TORONTO, Ontario, April 19, 2021 – Auxly Cannabis Group Inc. (TSX.V – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, is pleased to announce an agreement with its strategic partner, Imperial Brands PLC (“Imperial Brands”) to amend certain provisions of its previously issued $123 million debenture (the “Debenture”) and investor rights agreement (the “Investor Rights Agreement”) dated September 25, 2019 (collectively, the “Amendments”). 

Pursuant to the Amendments, Imperial and Auxly have agreed to extend the maturity date of the Debenture by 24 months from September 25, 2022 to September 25, 2024.

The Amendments will also provide Imperial with the right, on an annual basis, to convert any or all of the accrued and unpaid interest on the Debenture then outstanding into Common Shares (the “Interest Conversion Election”), at a conversion price equal to the five-day volume weighted average trading price of the Common Shares on the date that Interest Conversion Election is made.  Auxly and Imperial have also agreed that the interest rate under the Debenture, which currently accrues at a rate of 4% per annum and is payable annually, will remain unchanged but will be payable on maturity of the Debenture.

Lastly, the Amendments provide for the re-instatement of certain approval rights of Imperial under the Investor Rights Agreement.

As a result of the Amendments, the Company will see a significant improvement to the near-term cash requirements of the business, enabling it to focus on executing on its business strategies that will position it for long-term growth to the benefit of its stakeholders.

“After the great progress we’ve made over our first year of commercial operations, including achieving the #1 position in the 2.0 market and breaking into the top 10 licensed producers by overall market share, this agreement to extend the debt maturity date for 24 months demonstrates the confidence Imperial Brands has in our strong growth and differentiated strategy,” said Hugo Alves, CEO of Auxly.  “The extension and deferral of interest will improve our cash position, strengthen our balance sheet and remove potential overhang on the Company’s share price.  I would like to thank our partners at Imperial Brands for their ongoing commitment to our Company and look forward to our continued relationship.”

Auxly remains Imperial Brands’ exclusive global partner for any future development, manufacture, commercialization, sale and distribution of cannabis products.

The Debentures are convertible into Common Shares at a price of $0.81 per share at any time prior to the close of business on the business day immediately preceding maturity. 

The implementation of the Amendments is subject to the satisfaction of a number of conditions, including, among other things, the approval of the TSX Venture Exchange, and minority shareholder approval of the Amendments in accordance with Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), as more particularly described below.

Related Party Transaction

Imperial is considered a “related party” of the Company, and the Amendments constitute a “related party transaction”, as such terms are defined by MI 61-101. The Company is relying on an exemption from the formal valuation requirements of MI 61-101 available on the basis of the securities of the Company not being listed on specified markets prescribed by MI 61-101.

Pursuant to MI 61-101, the Amendments are subject to the approval by shareholders of the Company holding more than 50% Common Shares represented in person or by proxy at a duly constituted meeting of the shareholders of the Company, excluding the votes attaching to the Common Shares held by Imperial and its associates and affiliates (the “Minority Shareholder Approval”). The Company intends to obtain the Minority Shareholder Approval at its upcoming annual and special meeting of shareholders (the “Company Meeting”). Further particulars of the Amendments will be specified in the management information circular that will be sent to shareholders in advance of the Company Meeting.

ON BEHALF OF THE BOARD

“Hugo Alves” CEO

About Auxly Cannabis Group Inc. (TSX.V: XLY)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team: 

Email: IR@auxly.com

Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:

Email: press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: obtaining the necessary regulatory approval and Minority Shareholder Approval for the Amendments and the timing of such approvals; the anticipated benefits of the Amendments; the Company’s execution of its product development and commercialization strategy; consumer preferences, political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: the Company is able to obtain regulatory approval and Minority Shareholder Approval for the Amendments on the proposed terms and timeline; the expected benefits of the Amendments materialize in the manner expected, or at all; there is acceptance and demand for current and future Company products by consumers and provincial purchasers; and general economic, financial market, legislative, regulatory and political conditions in which the Company operates will remain the same. Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2019 dated May 13, 2020.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Auxly Receives Final Approval To Graduate To The Toronto Stock Exchange

TORONTO, Ontario, April 16, 2021 – Auxly Cannabis Group Inc. (TSX.V – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, is pleased to announce that it has received final approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (“TSXV”) and list its common shares on the TSX.

Auxly’s common shares will commence trading on the TSX at market open on Tuesday, April 20, 2021 under its existing symbol “XLY”. In connection with listing on the TSX, the last day of trading on the TSXV will be April 19, 2021 and the Company’s shares will be delisted from the TSXV upon commencement of trading on the TSX. The Company’s shares will continue to trade on the OTCQX market under the symbol “CBWTF.”  Shareholders will not be required to take any action in connection with the graduation and listing on the TSX.

ON BEHALF OF THE BOARD

“Hugo Alves” CEO

About Auxly Cannabis Group Inc. (TSX.V: XLY)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team: 

Email: IR@auxly.com

Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:

Email: press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the listing of the Company’s common shares on the TSX; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: general economic, financial market, legislative, regulatory, competitive and political conditions in which the Company operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View on GlobeNewswire.